Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
10. August 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Added to Russell 3000® Index
29. Juni 2020 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares
26. Juni 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 26, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel...
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
24. Juni 2020 08:31 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
23. Juni 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel...
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
08. Juni 2020 16:01 ET
|
Soleno Therapeutics
Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia Significant Positive Changes Also Seen in Two of...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
12. Mai 2020 16:01 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity
23. April 2020 08:00 ET
|
Soleno Therapeutics
Paper Published in Peer-Reviewed Journal, Genes, as Part of Special Supplement on Genetics of Prader-Willi Syndrome (PWS) DCCR is the first K-ATP Channel activator being developed for PWS Company...
Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference
11. März 2020 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
04. März 2020 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...